Scientific Sessions 2025  /  AF Lifestyle Therapy: Drugs Beyond Heart Failure and Obesity  /  Icosapent Ethyl in Patients With and Without Atrial Fibrillation (REDUCE IT)
Logo

American Heart Association

  51
  0

Final ID:

Icosapent Ethyl in Patients With and Without Atrial Fibrillation (REDUCE IT)

  • Olshansky, Brian  ( Iowa City VA Hospital , Iowa City , Iowa , United States )
  • Reiffel, James  ( Columbia University , Jupiter , Florida , United States )
    • Author Disclosures:
    Brian Olshansky: DO NOT have relevant financial relationships | James Reiffel: DO have relevant financial relationships ; Consultant:Sanofi:Past (completed) ; Consultant:Roivant:Past (completed) ; Consultant:InCarda Therapeutics:Past (completed) ; Researcher:Amarin:Past (completed) ; Researcher:J&J:Active (exists now) ; Advisor:Acesion:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

AF Lifestyle Therapy: Drugs Beyond Heart Failure and Obesity

Friday, 11/07/2025 , 12:30PM - 01:45PM

Cardiovascular Seminar

More abstracts on this topic:
Modifiable risk factors for atrial fibrillation

Albert Christine, Sanders Prashanthan

SGLT2 inhibitors vs GLP 1 inhibitors for sleep apnea and atrial fibrillation

Dominic Paari, Kalman Jonathan

More abstracts from these authors:
Atrial Fibrillation: Why Are We Hiding Reality?

Reiffel James

Medical management of cardiac dysautonomias: How successful are we?

Olshansky Brian

You have to be authorized to contact abstract author. Please, Login
Not Available